Overview

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.
Phase:
Phase 3
Details
Lead Sponsor:
Padagis LLC
Perrigo Company
Collaborators:
IMPAX Laboratories, Inc.
Impax Laboratories, LLC
Treatments:
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate